Allergan recently launched Lastacaft ((alcaftadine ophthalmic solution) 0.25%. Lastacaft is an H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. The product offers once-daily dosing and works fast to prevent all-day itching. Lastacaft had its safety evaluated in a randomized clinical study of 909 patients, is classified as a Pregnancy Category B product and has not been tested in patients under the age of 2. 

Visit www.allergan.com.